Lumida
/ATAI
⌘K
ATAI Life Sciences NV

ATAI Life Sciences NV

ATAI
$7.35USD+0.82%+0.06 today

MARKET CAP

2.7B

P/E (TTM)

FWD P/E

DAY RANGE

$7 – $7

52W RANGE

$3
$7

AI Summary

Stalk
StalkMedium

ATAI maintains its Stage 2 uptrend, but the active Bullish Exhaustion inflection pattern and recent pullback from highs signal waning upside momentum. Under a Speculative strategy, bullish engagement should be deferred to pullbacks into the rising 9/20 EMA support area for better asymmetry.

  • $430.3M cash & equivalents funds operations through 2023
  • 11 clinical programs targeting mental health disorders
  • Q2 revenue $1.7M, down 142.8% YoY, highlighting weak top line
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024TREND
Sales, Adj.$20.4M$233,000$314,000$308,000
YoY %-98.9%+34.8%-1.9%
P / Sales51.8x1771.1x854.9x691.6x
EV / Sales35.4x1123.3x868.0x773.8x
Gross Profit, Adj.$20.4M$233,000$314,000$308,000
YoY %-98.9%+34.8%-1.9%
Margin %100.0%100.0%100.0%100.0%
EV / Gross Profit35.4x1123.3x868.0x773.8x
EBITDA, Adj.$-135.8M$-144.6M$-125.2M$-102.2M
YoY %-6.5%+13.5%+18.3%
Margin %-666.3%-62068.2%-39857.3%-33187.7%
EV / EBITDA-5.3x-1.8x-2.2x-2.3x
EBIT$-135.8M$-144.8M$-125.5M$-102.7M
YoY %-6.6%+13.3%+18.2%
Margin %-666.5%-62140.3%-39958.9%-33341.2%
EV / EBIT-5.3x-1.8x-2.2x-2.3x
Net Income$-167.8M$-152.4M$-40.2M$-149.3M
YoY %+9.2%+73.6%-271.1%
Net Margin-823.6%-65401.3%-12810.2%-48464.0%
EPS (GAAP)-$1.21-$0.98-$0.25-$0.93
YoY %+19.0%+74.5%-272.0%